A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
Completed · Phase 1 · Has a placebo group
Conditions studied: Dyslipidemia
In brief
This is a two-part Phase 1 placebo-controlled, double-blind, randomized single and multiple ascending dose study. In Part A, CAT-2003 is administered as a single dose; at two doses (1000 and 2000 mg), subjects will return for a second dose of CAT-2003 or placebo after a high fat meal. In Part B, CAT-2003 is administered for 14 consecutive days.
Key facts
- Study ID
- NCT01725594
- Run by
- Catabasis Pharmaceuticals
- People needed
- 99
- Starts
- 2012-11-01
- Expected to finish
- 2013-05-01
- Last updated by the study team
- 2013-07-11
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Medpace CPU — Cincinnati, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.